Reportlinker Adds Nycomed S.C.A. SICAR: PharmaVitae Profile
NEW YORK, April 1 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:
Nycomed S.C.A. SICAR: PharmaVitae Profile
http://www.reportlinker.com/p0184960/Nycomed-SCA-SICAR-PharmaVitae-Profile.html
Introduction
This analysis examines the historical and forecast performance for Nycomed in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
*Benchmark Nycomed's performance against key rivals in the prescription pharmaceutical sector
*Determine the historical impact of M&A on Nycomed's specialty pharmaceutical business model
*Examine Nycomed's growth potential in the face of a blockbuster patent expiry
ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 7
Nycomed: PharmaVitae forecasts at a glance 8
Strategic insight 9
Historical growth led by Altana acquisition 9
Near-term operating performance threatened by reduced pantoprazole sales 10
M&A extends geographical reach to global scale 10
SWOT analysis 11
TABLE OF CONTENTS 12
Table of figures 14
Chapter 3 Quarterly news update 15
Product developments 15
Deals and alliances 16
Product deals 16
Company announcements 17
Chapter 4 Company introduction 18
Key findings 18
Background 19
Key corporate developments 19
M&A history 20
Chapter 5 Company sales 22
Key findings 22
Prescription pharmaceutical sales and growth rate analysis, 2002-14 23
Product analysis 24
Product analysis, 2002-08 25
Product analysis, 2008-14 27
Therapy area analysis 30
Geographic analysis 32
Launch/core/expiry analysis 34
Explanation of launch/core/expiry analysis 34
Launch analysis, 2008-14 35
Core analysis, 2008-14 36
Expiry analysis, 2008-14 37
Launch/core/expiry configuration, 2008-14 38
Molecule type analysis 39
Externalization analysis 41
Chapter 6 Company financials 43
Key findings 43
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 44
Operating costs and profit analysis 45
Operating costs and profit analysis, 2002-08 46
Operating cost ratio and profit margin analysis, 2002-08 47
Operating cost ratio and profit margin analysis, 2008-14 48
Operating costs and profit analysis, 2008-14 49
Chapter 7 Key products and competitors 50
Key findings 50
Overview 51
Gastroenterology 52
Pantoprazole 52
Overview 52
Sales forecast 53
Sales remain strong despite generic encroachment in the US 54
Efficacy favors Protonix in an already genericized market 55
Respiratory 56
Alvesco 56
Overview 56
Sales forecast 57
New once-daily inhaled corticosteroid for asthma 57
US licensing agreement reached with respiratory specialist Sepracor 57
Asthma market overview 57
Ciclesonide safety advantages could help overcome barriers to uptake 58
Alvesco forecast assumptions 59
Omnaris 60
Overview 60
Sales forecast 61
Allergic rhinitis launch adds significant value to franchise 61
Daxas 62
Overview 62
Sales forecast 63
Commercial attractiveness 65
Genitourinary 66
Preotact 66
Overview 66
Sales forecast 67
Novel medication for high fracture risk postmenopausal osteoporosis 67
Preotact offers novel administration and MOA 67
Chapter 8 Appendix 69
R&D pipeline 69
References 70
Abbreviations 70
Exchange rates 72
About Datamonitor 73
About Datamonitor Healthcare 73
Datamonitor consulting 73
Disclaimer 75
LIST OF TABLES
Table 1: Nycomed - PharmaVitae forecasts at a glance 8
Table 2: Nycomed operating cost ratio analysis (% of total revenues), 2002-08 9
Table 3: Nycomed key product developments, 2009 15
Table 4: Nycomed product deals and alliances, 2009 16
Table 5: Nycomed company announcements, 2009 17
Table 6: Nycomed product portfolio overview ($m), 2002-08 25
Table 7: Nycomed product portfolio overview ($m), 2008-14 27
Table 8: Nycomed prescription pharmaceutical sales by therapy area ($m), 2008-14 31
Table 9: Nycomed prescription pharmaceutical sales by geographic region ($m), 2008-14 33
Table 10: Nycomed launch portfolio overview ($m), 2008-14 35
Table 11: Nycomed core portfolio overview ($m), 2008-14 36
Table 12: Nycomed expiry portfolio overview ($m), 2008-14 37
Table 13: Nycomed prescription pharmaceutical sales by molecule type ($m), 2008-14 40
Table 14: Nycomed prescription pharmaceutical sales by source ($m), 2008-14 42
Table 15: Total Nycomed sales by business unit ($m), 2002-08 44
Table 16: Nycomed operating revenue/cost analysis ($m), 2002-08 46
Table 17: Nycomed operating cost ratio analysis (% of total revenues), 2002-08 47
Table 18: Nycomed operating cost ratio analysis (% of total revenues), 2008-14 48
Table 19: Nycomed operating revenue/cost analysis ($m), 2008-14 49
Table 20: Key products overview 51
Table 21: Pantoprazole: overview 52
Table 22: Pantoprazole: sales forecast ($m), 2008-14 53
Table 23: Alvesco: overview 56
Table 24: Alvesco: sales forecast ($m), 2008-14 57
Table 25: Omnaris: overview 60
Table 26: Omnaris: sales forecast ($m), 2008-14 61
Table 27: Daxas: overview 62
Table 28: Daxas: sales forecast ($m), 2008-14 63
Table 29: Preotact: overview 66
Table 30: Preotact: sales forecast ($m), 2008-14 67
Table 31: Nycomed's R&D pipeline (Phase I-registration) 69
Table 32: Exchange rates, 2009 72
LIST OF FIGURES
Figure 1: The PharmaVitae Explorer 3
Figure 2: Nycomed prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6
Figure 3: Nycomed's financial performance ($m), 2002-14 7
Figure 4: Nycomed SWOT analysis 11
Figure 5: Nycomed prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 23
Figure 6: Key product sales ($m), 2002-14 24
Figure 7: Nycomed key sales growth drivers and resistors ($m), 2002-08 26
Figure 8: Nycomed key sales growth drivers and resistors ($m), 2008-14 28
Figure 9: Nycomed prescription pharmaceutical sales by therapy area ($m), 2002-14 30
Figure 10: Nycomed prescription pharmaceutical sales by geographic region ($m), 2002-14 32
Figure 11: Nycomed launch/core/expiry configuration ($m), 2008-14 38
Figure 12: Nycomed prescription pharmaceutical sales by molecule type ($m), 2002-14 39
Figure 13: Nycomed prescription pharmaceutical sales by source ($m), 2002-14 41
Figure 14: Nycomed operating revenue/cost analysis ($m), 2002-14 45
To order this report:
Pharmaceutical Industry: Nycomed S.C.A. SICAR: PharmaVitae Profile
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article